The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Jagdish Umakant Nayak
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 16.9 pts more than Nifty Microcap 250 and 18.9 pts more than its Healthcare Service Provider peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Jagdish Umakant Nayak, Promoter and Managing Director of Clinitech Laboratory Ltd, has disclosed the purchase of 3,600 equity shares on March 10, 2026, through the open market under Regulation 29(2) of SEBI (SAST) Regulations, 2011. His shareholding increased from 6,93,700 shares (30.39%) to 6,97,300 shares (30.55%) of the company. The total equity share capital of the company remains unchanged at 22,82,400 shares. This is a small incremental acquisition by the promoter in his existing capacity.
This is a minor open market purchase by the promoter, increasing his stake by just 0.16 percentage points. It signals continued promoter confidence in the company, though the quantum is too small to materially affect shareholding structure or stock price.